Evommune (EVMN) Accounts Payables (2024 - 2026)

Evommune (EVMN) posted quarterly Accounts Payables of $4.0 million for Q1 2026, down 47.85% quarter-over-quarter from $7.8 million in Q4 2025.

Evommune (EVMN) Accounts Payables (2024 - 2026) Analysis & Trends

Evommune (EVMN) has reported Accounts Payables for 3 consecutive years, with $4.0 million the latest figure, recorded in Q1 2026.

In Q1 2026, Accounts Payables changed N/A year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (changed N/A YoY), while the FY2025 annual figure was $7.8 million, down 6.15% from the prior year.
Accounts Payables fell to $4.0 million in Q1 2026 per EVMN's latest filing, from $7.8 million in the prior quarter.
Across five years, Accounts Payables topped out at $8.3 million in Q4 2024 and bottomed at $3.6 million in Q3 2025.
Historically, Accounts Payables has averaged $5.9 million across 3 years, with a median of $5.9 million in 2025.
On a YoY basis, Accounts Payables climbed as much as 6.15% in 2025 and fell as far as 6.15% in 2025.
Evommune's Accounts Payables stood at $8.3 million in 2024, then decreased by 6.15% to $7.8 million in 2025, then tumbled by 47.85% to $4.0 million in 2026.
Business Quant data shows EVMN's Accounts Payables at $4.0 million in Q1 2026, $7.8 million in Q4 2025, and $3.6 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Accounts Payables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	429.50 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.16 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.52 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	88.42 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	470.30 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	3.05 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	35.57 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	108.02 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	428.93 Mn
10	Evommune	531.53 Mn	330.73 Mn	-	5.04 Mn

Download Data